Sugi Predict

Sugi Predict / Compounds / SCHEMBL16094381

SCHEMBL16094381

SCHEMBL16094381

C=Cc1ccc(C(=O)O)cc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ P4HB P07237 1/20 0.44
▸ RXRA P19793 3/20 0.41
▸ RXRB P28702 3/20 0.41
▸ RXRG P48443 3/20 0.41
▸ SRD5A2 P31213 3/20 0.41
▸ TTR P02766 1/20 0.40
▸ ADH5 P11766 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ IP6K1 Q92551 1/20 0.37
▸ IP6K3 Q96PC2 1/20 0.37
▸ IP6K2 Q9UHH9 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL988152 0.84 SMN1; SMN2 (0.46) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL31455608 0.81 NOTUM (0.57) SMN1; SMN2P4HBTDP1MRGPRX4HSD17B10
SCHEMBL3903479 0.81 NOTUM (0.57) SMN1; SMN2P4HBTDP1MRGPRX4HSD17B10
SCHEMBL827082 0.77 RXRA (0.48) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL31319449 0.77 RXRA (0.48) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL4096586 0.77 LMNA (0.49) P4HBSRD5A2TTRTDP1HSD17B10
SCHEMBL6304560 0.77 RXRA (0.44) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL336261 0.76 ADH5 (0.54) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL11828554 0.76 RXRA (0.47) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL7026695 0.76 CES2 (0.50) SMN1; SMN2P4HBRXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108467369-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2021-08-20 — — CN disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 — — EP disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 — — US disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 — — US disclosed
US-9408793-B2 Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-08-09 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
CN-105143209-A Biaryl amide compounds as kinase inhibitors NOVARTIS AG 2015-12-09 — — CN disclosed
US-20150190323-A1 SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-07-09 — — US disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-8802850-B2 Cyclopropyl modulators of P2Y12 receptor AUSPEX PHARMACEUTICALS, INC. (US) 2014-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150190323-A1 SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS CYP26A1, CYP21A2, CYP26B1 SMN1; SMN2 3516/4885P4HB 847/4885RXRA 233/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS SMN1; SMN2 3547/4885P4HB 3679/4885RXRA 2123/4885
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885P4HB 3679/4885RXRA 2123/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885P4HB 3679/4885RXRA 2123/4885
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885P4HB 3679/4885RXRA 2123/4885
US-10245267-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS SMN1; SMN2 3547/4885P4HB 3679/4885RXRA 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.